Shikari® Trastuzumab ELISA Kit

Trastuzumab is a recombinant humanized monoclonal antibody that targets the HER-2 receptor, a transmembrane tyrosine kinase overexpressed in certain cancers, notably HER-2 positive breast cancer. HER-2 amplification results in the hyperactivation of intracellular signaling pathways, including MAPK and PI3K/Akt, leading to increased cell proliferation and survival. Trastuzumab binds specifically to the extracellular domain of HER-2, inhibiting downstream signaling, promoting receptor downregulation, and blocking tumor cell proliferation.

In clinical settings, trastuzumab has revolutionized the treatment of HER-2 positive cancers by improving survival outcomes and reducing recurrence rates. It exerts antitumor effects both by direct inhibition of HER-2 signaling and through immune-mediated mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Trastuzumab is approved for use in early-stage and metastatic breast cancer, as well as in certain gastric cancers exhibiting HER-2 overexpression.

In research, trastuzumab serves as a model for studying HER-2 signaling, resistance mechanisms, and immune-oncology interactions. Therapeutic drug monitoring (TDM) of trastuzumab, especially in patients exhibiting resistance or suboptimal response, helps optimize dosing and manage treatment efficacy. Furthermore, its biosimilars are under evaluation and use worldwide, expanding access and offering cost-effective alternatives in oncology care.

This product is manufactured in Turkey by Matriks Biotek.